We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
126
Cogent Biosciences
COGT
$6.65B
$1.32M 0.05%
+146,911
New +$1M
RNAM
127
DELISTED
Avidity Biosciences
RNAM
$1.24M 0.05%
85,218
+58,766
+222% +$874K
ASRT
128
DELISTED
Assertio
ASRT
$1.21M 0.05%
27,372
– –
WAT icon
129
Waters Corp
WAT
$37B
$1.19M 0.05%
3,600
-24,861
-87% -$7.89M
GRTX
130
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.17M 0.05%
898,374
– –
STVN icon
131
Stevanato
STVN
$5.42B
$1.13M 0.04%
71,190
– –
SNDX icon
132
Syndax Pharmaceuticals
SNDX
$1.69B
$1.09M 0.04%
56,480
– –
ACAD icon
133
Acadia Pharmaceuticals
ACAD
$4.43B
$1.02M 0.04%
72,225
– –
MORF
134
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$968K 0.04%
44,625
+9,600
+27% +$268K
PTGX icon
135
Protagonist Therapeutics
PTGX
$8.79B
$967K 0.04%
122,271
– –
ACET icon
136
Adicet Bio
ACET
$85.2M
$925K 0.04%
3,958
– –
XENE icon
137
Xenon Pharmaceuticals
XENE
$6.06B
$904K 0.04%
+29,710
New +$899K
STRO icon
138
Sutro Biopharma
STRO
$401M
$854K 0.03%
16,392
– –
FATE icon
139
Fate Therapeutics
FATE
$286M
$784K 0.03%
31,652
– –
NTRA icon
140
Natera
NTRA
$38.3B
$758K 0.03%
+21,400
New +$792K
ICPT
141
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$719K 0.03%
52,067
– –
DHC
142
Diversified Healthcare Trust
DHC
$2.15B
$651K 0.03%
357,720
– –
TCRX icon
143
TScan Therapeutics
TCRX
$48.6M
$629K 0.02%
200,000
– –
BEAM icon
144
Beam Therapeutics
BEAM
$2.63B
$612K 0.02%
15,817
– –
NHI icon
145
National Health Investors
NHI
$3.72B
$608K 0.02%
10,038
– –
UHT
146
Universal Health Realty Income Trust
UHT
$603M
$599K 0.02%
11,258
– –
SRRK icon
147
Scholar Rock
SRRK
$5.67B
$597K 0.02%
108,833
– –
THRX
148
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$553K 0.02%
100,000
– –
CHCT
149
Community Healthcare Trust
CHCT
$523M
$540K 0.02%
14,900
– –
ALXO icon
150
ALX Oncology
ALXO
$261M
$536K 0.02%
66,211
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.